MiR-451a and IL18 Can Differentiate Familial Mediterranean Fever Patients in Attack and Remission Periods: a Prospective Cross-sectional Study

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2025 Feb 11

PMID 39934489

Authors

Menderes Yusuf Terzi

Oguzhan Ozcan

Gezmis Kimyon

Hamza Malik Okuyan

Abdullah Arpaci

Serdar Dogan

Affiliations

Soon will be listed here.

Abstract

Objectives: Familial Mediterranean fever (FMF) is a multifaceted autoimmune disease and requires a diligent strategical approach considering disease periods and mutation subtypes. We aimed to investigate serum levels of autoimmunity-related cell-free miRNAs and inflammatory and apoptotic markers in FMF patients.

Methods: Sixty FMF patients, of which 30 were in attack (FMF-A) and 30 were in remission (FMF-R) periods, and 25 age-, sex-, and BMI-matched healthy controls were included in our study. The expression levels of miR-26a-5p, miR-146a-5p, miR-155-2-5p, and miR-451a were analyzed with reverse-transcriptase quantitative polymerase chain reaction, and protein levels of interleukin-18 (IL18) and soluble Fas cell surface death receptor (sFAS) were measured with enzyme-linked immunosorbent assay. Serum CRP levels were analyzed by nephelometry, ferritin levels by chemiluminescence, and routine biochemical parameters by spectrophotometry. Correlation analyses were performed to seek potential associations of miRNAs with serum markers and biochemical parameters. Potential biomarkers were tested with receiver operating characteristic analysis.

Results: We observed elevated serum IL18 levels but not sFAS, in FMF patients, particularly during attack period. IL18 demonstrated diagnostic value and was significantly correlated with acute-phase markers namely CRP, fibrinogen, and ferritin. Altered levels of IL18 and miR-451a could distinguish FMF patients in the attack period from the ones in remission. miR-26a-5p, miR-146a-5p, and miR-155-2-5p were downregulated in FMF patients carrying M694V mutations.

Conclusions: These findings suggest that IL18 and specific miRNAs can serve as potential biomarkers for FMF pathogenesis. Discovering promising targets for FMF-related miRNAs using mechanistic strategies will enhance our understanding of FMF disease management and therapy. Key Points • miR-451a and IL18 can serve as an indicator in distinguishing familial Mediterranean fever patients in attack and remission periods. • miR-26a-5p, miR-146a-5p, and miR-155-2-5p were dysregulated in FMF patients carrying M694V mutation.

References

SOHAR E, Gafni J, Pras M, Heller H . Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967; 43(2):227-53. DOI: 10.1016/0002-9343(67)90167-2. View

Gershoni-Baruch R, Shinawi M, Leah K, Badarnah K, Brik R . Familial Mediterranean fever: prevalence, penetrance and genetic drift. Eur J Hum Genet. 2001; 9(8):634-7. DOI: 10.1038/sj.ejhg.5200672. View

Chae J, Wood G, Richard K, Jaffe H, Colburn N, Masters S . The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood. 2008; 112(5):1794-803. PMC: 2518886. DOI: 10.1182/blood-2008-01-134932. View

Kim M, Chae J, Park Y, De Nardo D, Stirzaker R, Ko H . Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1β. J Exp Med. 2015; 212(6):927-38. PMC: 4451132. DOI: 10.1084/jem.20142384. View

Manukyan G, Aminov R . Update on Pyrin Functions and Mechanisms of Familial Mediterranean Fever. Front Microbiol. 2016; 7:456. PMC: 4815028. DOI: 10.3389/fmicb.2016.00456. View

Booty M, Chae J, Masters S, Remmers E, Barham B, Le J . Familial Mediterranean fever with a single MEFV mutation: where is the second hit?. Arthritis Rheum. 2009; 60(6):1851-61. PMC: 2753538. DOI: 10.1002/art.24569. View

Moradian M, Sarkisian T, Ajrapetyan H, Avanesian N . Genotype-phenotype studies in a large cohort of Armenian patients with familial Mediterranean fever suggest clinical disease with heterozygous MEFV mutations. J Hum Genet. 2010; 55(6):389-93. DOI: 10.1038/jhg.2010.52. View

Gandhi R, Healy B, Gholipour T, Egorova S, Musallam A, Hussain M . Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol. 2013; 73(6):729-40. DOI: 10.1002/ana.23880. View

Singh R, Massachi I, Manickavel S, Singh S, Rao N, Hasan S . The role of miRNA in inflammation and autoimmunity. Autoimmun Rev. 2013; 12(12):1160-5. DOI: 10.1016/j.autrev.2013.07.003. View

10.

Amarilyo G, Pillar N, Ben-Zvi I, Weissglas-Volkov D, Zalcman J, Harel L . Analysis of microRNAs in familial Mediterranean fever. PLoS One. 2018; 13(5):e0197829. PMC: 5963758. DOI: 10.1371/journal.pone.0197829. View

11.

Orsdemir Hortu H, Karaca E, Sozeri B, Gulez N, Makay B, Gunduz C . Evaluation of the effects of miRNAs in familial Mediterranean fever. Clin Rheumatol. 2018; 38(3):635-643. DOI: 10.1007/s10067-017-3914-0. View

12.

Karpuzoglu E, Kisla Ekinci R, Balci S, Bisgin A, Yilmaz M . Altered expression of apoptosis-related, circulating cell-free miRNAs in children with familial Mediterranean fever: a cross-sectional study. Rheumatol Int. 2020; 41(1):103-111. DOI: 10.1007/s00296-020-04541-4. View

13.

Koga T, Migita K, Sato S, Umeda M, Nonaka F, Kawashiri S . Multiple Serum Cytokine Profiling to Identify Combinational Diagnostic Biomarkers in Attacks of Familial Mediterranean Fever. Medicine (Baltimore). 2016; 95(16):e3449. PMC: 4845848. DOI: 10.1097/MD.0000000000003449. View

14.

Manukyan G, Ghazaryan K, Ktsoyan Z, Tatyan M, Khachatryan Z, Hakobyan G . Cytokine profile of Armenian patients with Familial Mediterranean fever. Clin Biochem. 2008; 41(10-11):920-2. DOI: 10.1016/j.clinbiochem.2008.03.017. View

15.

Koga T, Migita K, Sato T, Sato S, Umeda M, Nonaka F . MicroRNA-204-3p inhibits lipopolysaccharide-induced cytokines in familial Mediterranean fever via the phosphoinositide 3-kinase γ pathway. Rheumatology (Oxford). 2018; 57(4):718-726. DOI: 10.1093/rheumatology/kex451. View

16.

Abdgawad M, Pettersson A, Gunnarsson L, Bengtsson A, Geborek P, Nilsson L . Decreased neutrophil apoptosis in quiescent ANCA-associated systemic vasculitis. PLoS One. 2012; 7(3):e32439. PMC: 3293802. DOI: 10.1371/journal.pone.0032439. View

17.

Liphaus B, Kiss M, Carrasco S, Palmeira P, Goldenstein-Schainberg C, Carneiro-Sampaio M . Increased serum sFas, sTRAIL, and reduced sFasL in juvenile-onset systemic lupus erythematosus. Clin Rheumatol. 2017; 36(12):2847-2852. DOI: 10.1007/s10067-017-3615-8. View

18.

Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T . Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997; 40(10):1879-85. DOI: 10.1002/art.1780401023. View

19.

Cui C, Zhong B, Fan R, Cui Q . HMDD v4.0: a database for experimentally supported human microRNA-disease associations. Nucleic Acids Res. 2023; 52(D1):D1327-D1332. PMC: 10767894. DOI: 10.1093/nar/gkad717. View

20.

Okuyan H, Begen M . miRNAs as attractive diagnostic and therapeutic targets for Familial Mediterranean Fever. Mod Rheumatol. 2021; 31(5):949-959. DOI: 10.1080/14397595.2020.1868674. View